abstract: UNASSIGNED: Primary @entity1 (PI) are defects of the immune system that cause severe, sometimes life-threatening, infections if not diagnosed and treated appropriately. Many @entity0 with PI are undiagnosed, under-diagnosed, or misdiagnosed. To raise awareness and assure earliest diagnosis, appropriate treatment, and proper care management, the Jeffrey Modell Foundation (JMF) implemented a physician education and public awareness program beginning in 2003. Data are requested annually from physician experts within the Jeffrey Modell Centers Network  (JMCN), consisting of 602 expert physicians, at 253 academic institutions, in 206 cities, and 84 countries spanning six continents. Center Directors reported on @entity0 ' specific @entity3 and treatment modalities including immunoglobulins, transplantation, and gene therapy as well as data on gender and age. Center Directors also provided physician-reported @entity0 outcomes as well as pre- and post-diagnosis differences. Costs were assigned to these factors. In collaboration with the Network, JMF advocated, funded, and implemented population-based newborn screening for severe @entity1 and @entity2 , covering 96.2  % of all newborns in the US. Finally, 21 JMF Centers participated in a polio surveillance study of @entity0 with PI who either received or have been exposed to the oral polio vaccine. These initiatives have led to an overall better understanding of the immune system and will continue to improve quality of life for those with PI.

title: Primary XXXX worldwide: an updated overview from the Jeffrey Modell Centers Global Network.

answer: @entity1


abstract: BACKGROUND: This paper documents a retrospective pilot study of a novel approach for treating @entity1 ( @entity1 ) with @entity2 precursors of @entity3 and @entity4 in conjunction with urinary @entity5 assays subjected to organic cation transporter (OCT) functional status determination. The goal of this research was to document the findings and related considerations of a retrospective chart review study designed to identify issues and areas of concern that will define parameters for a prospective controlled study. METHODS: This study included 85 @entity0 , aged 4-18 years, who were treated with a novel @entity2 precursor protocol. Their clinical course during the first 8-10 weeks of treatment was analyzed retrospectively. The study team consisted of PhD clinical psychologists, individuals compiling clinical data from records, and a statistician. The @entity0 had been treated with a predefined protocol for administering @entity2 precursors of @entity3 and @entity4 , along with OCT assay interpretation as indicated. RESULTS: In total, 67% of @entity0 achieved significant improvement with only @entity2 precursors of @entity3 and @entity4 . In @entity0 who achieved no significant relief of symptoms with only @entity2 precursors, OCT assay interpretation was utilized. In this subgroup, 30.3% achieved significant relief following two or three urine assays and dosage changes as recommended by the assay results. The total percentage of @entity0 showing significant improvement was 77%. CONCLUSION: The efficacy of this novel protocol appears superior to some @entity1 prescription drugs, and therefore indicates a need for further studies to verify this observation. The findings of this study justify initiation of further prospective controlled studies in order to evaluate more formally the observed benefits of this novel approach in the treatment of @entity1 .

title: Treatment of XXXX with @entity5 @entity2 precursors and organic cation transporter assay interpretation.

answer: @entity1


abstract: BACKGROUND: This paper documents a retrospective pilot study of a novel approach for treating @entity1 ( @entity1 ) with @entity2 precursors of @entity3 and @entity4 in conjunction with urinary @entity5 assays subjected to organic cation transporter (OCT) functional status determination. The goal of this research was to document the findings and related considerations of a retrospective chart review study designed to identify issues and areas of concern that will define parameters for a prospective controlled study. METHODS: This study included 85 @entity0 , aged 4-18 years, who were treated with a novel @entity2 precursor protocol. Their clinical course during the first 8-10 weeks of treatment was analyzed retrospectively. The study team consisted of PhD clinical psychologists, individuals compiling clinical data from records, and a statistician. The @entity0 had been treated with a predefined protocol for administering @entity2 precursors of @entity3 and @entity4 , along with OCT assay interpretation as indicated. RESULTS: In total, 67% of @entity0 achieved significant improvement with only @entity2 precursors of @entity3 and @entity4 . In @entity0 who achieved no significant relief of symptoms with only @entity2 precursors, OCT assay interpretation was utilized. In this subgroup, 30.3% achieved significant relief following two or three urine assays and dosage changes as recommended by the assay results. The total percentage of @entity0 showing significant improvement was 77%. CONCLUSION: The efficacy of this novel protocol appears superior to some @entity1 prescription drugs, and therefore indicates a need for further studies to verify this observation. The findings of this study justify initiation of further prospective controlled studies in order to evaluate more formally the observed benefits of this novel approach in the treatment of @entity1 .

title: Treatment of @entity1 with @entity5 XXXX precursors and organic cation transporter assay interpretation.

answer: @entity2


abstract: BACKGROUND: This paper documents a retrospective pilot study of a novel approach for treating @entity1 ( @entity1 ) with @entity2 precursors of @entity3 and @entity4 in conjunction with urinary @entity5 assays subjected to organic cation transporter (OCT) functional status determination. The goal of this research was to document the findings and related considerations of a retrospective chart review study designed to identify issues and areas of concern that will define parameters for a prospective controlled study. METHODS: This study included 85 @entity0 , aged 4-18 years, who were treated with a novel @entity2 precursor protocol. Their clinical course during the first 8-10 weeks of treatment was analyzed retrospectively. The study team consisted of PhD clinical psychologists, individuals compiling clinical data from records, and a statistician. The @entity0 had been treated with a predefined protocol for administering @entity2 precursors of @entity3 and @entity4 , along with OCT assay interpretation as indicated. RESULTS: In total, 67% of @entity0 achieved significant improvement with only @entity2 precursors of @entity3 and @entity4 . In @entity0 who achieved no significant relief of symptoms with only @entity2 precursors, OCT assay interpretation was utilized. In this subgroup, 30.3% achieved significant relief following two or three urine assays and dosage changes as recommended by the assay results. The total percentage of @entity0 showing significant improvement was 77%. CONCLUSION: The efficacy of this novel protocol appears superior to some @entity1 prescription drugs, and therefore indicates a need for further studies to verify this observation. The findings of this study justify initiation of further prospective controlled studies in order to evaluate more formally the observed benefits of this novel approach in the treatment of @entity1 .

title: Treatment of @entity1 with XXXX @entity2 precursors and organic cation transporter assay interpretation.

answer: @entity5


abstract: OBJECTIVES: To determine the efficacy of physical therapy on @entity1 and physical function in @entity0 with @entity2 . DESIGN: Randomized, @entity0 - and assessor blinded controlled trial pilot study. METHODS: This trial was registered at ClinicalTrials.gov (NCT01814124) and reported according to Consolidated Standards of Reporting Trials (CONSORT) requirements. @entity0 were randomly assigned to receive either a combination of manual therapy and supervised exercise (MTEX), plus advice and home exercise or advice and home exercise alone (Ad+ @entity3 ) over six weeks. Primary outcomes were @entity1 (Visual Analog Scale) and physical function (Hip Outcome Score) at week seven. RESULTS: Fifteen @entity0 , mean age 33.7 (SD 9.5, 73% female) satisfied the eligibility criteria and completed week seven measurements. The between group differences for changes in @entity1 or physical function were not significant. Both groups showed statistically significant improvements in @entity1 : the MTEX group improved a mean of 17.6mm and the Ad+ @entity3 group, 18.0mm. CONCLUSIONS: The results of this pilot study provide preliminary evidence that symptomatic @entity2 may be amenable to conservative treatment strategies however further full-scale randomized controlled trials are required to demonstrate this. In this small pilot study, supervised manual therapy and exercise did not result in greater improvement in @entity1 or function compared to advice and home exercise in @entity0 with symptomatic @entity2 .

title: Non-operative management of XXXX : A prospective, randomized controlled clinical trial pilot study.

answer: @entity2


abstract: UNASSIGNED: @entity5 is originally derived from medicinal herb and used preferentially in treatment of @entity3 in Far East regions. @entity7 has strong anti-inflammatory and immune-regulatory properties, acting mainly through inhibiting NF-kB signaling. Although the upstream target through which @entity7 affects NF-kB activity is unknown, evidence suggests that @entity7 might regulate @entity2 through @entity4 signaling. In this study we explored the role of @entity4 in mediating @entity7 's anti- @entity2 and kidney protection in a @entity1 model of @entity0 . We found that @entity7 is an activator of @entity4 signaling. It markedly increased @entity4 protein level, @entity4 nuclear translocation, Nef2 transcription capacity, and the downstream protein expression. We further demonstrated that @entity7 activation of @entity4 is likely due to its repression of the @entity4 inhibitor @entity6 since it drastically reduced @entity6 protein through the PKC-sensitive ubiquitination-proteasomal degradation. @entity7 treatment of @entity0 @entity1 effectively reduced the @entity0 and inflammatory responses, @entity0 , and improved the pathological protein expression in an @entity4 dependent manner. In addition, @entity7 also @entity4 -dependently modulated macrophage M1/M2 polarization and inhibited the IkBa phosphorylation and NF-kB nuclear translocation, hence revealing an important upstream event that contributed to its anti- @entity2 and tissue protection. Taken together our study has identified a novel pathway through which @entity7 exerts its anti- @entity2 and renal protective functions, and provided a molecular basis for @entity7 potential applications in the treatment of kidney and other @entity2 .

title: @entity5 activation of @entity4 signaling prevents hyperactive @entity2 and XXXX in a @entity1 model of @entity0 .

answer: @entity0


abstract: UNASSIGNED: @entity5 is originally derived from medicinal herb and used preferentially in treatment of @entity3 in Far East regions. @entity7 has strong anti-inflammatory and immune-regulatory properties, acting mainly through inhibiting NF-kB signaling. Although the upstream target through which @entity7 affects NF-kB activity is unknown, evidence suggests that @entity7 might regulate @entity2 through @entity4 signaling. In this study we explored the role of @entity4 in mediating @entity7 's anti- @entity2 and kidney protection in a @entity1 model of @entity0 . We found that @entity7 is an activator of @entity4 signaling. It markedly increased @entity4 protein level, @entity4 nuclear translocation, Nef2 transcription capacity, and the downstream protein expression. We further demonstrated that @entity7 activation of @entity4 is likely due to its repression of the @entity4 inhibitor @entity6 since it drastically reduced @entity6 protein through the PKC-sensitive ubiquitination-proteasomal degradation. @entity7 treatment of @entity0 @entity1 effectively reduced the @entity0 and inflammatory responses, @entity0 , and improved the pathological protein expression in an @entity4 dependent manner. In addition, @entity7 also @entity4 -dependently modulated macrophage M1/M2 polarization and inhibited the IkBa phosphorylation and NF-kB nuclear translocation, hence revealing an important upstream event that contributed to its anti- @entity2 and tissue protection. Taken together our study has identified a novel pathway through which @entity7 exerts its anti- @entity2 and renal protective functions, and provided a molecular basis for @entity7 potential applications in the treatment of kidney and other @entity2 .

title: @entity5 activation of @entity4 signaling prevents hyperactive @entity2 and @entity0 in a @entity1 model of XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity5 is originally derived from medicinal herb and used preferentially in treatment of @entity3 in Far East regions. @entity7 has strong anti-inflammatory and immune-regulatory properties, acting mainly through inhibiting NF-kB signaling. Although the upstream target through which @entity7 affects NF-kB activity is unknown, evidence suggests that @entity7 might regulate @entity2 through @entity4 signaling. In this study we explored the role of @entity4 in mediating @entity7 's anti- @entity2 and kidney protection in a @entity1 model of @entity0 . We found that @entity7 is an activator of @entity4 signaling. It markedly increased @entity4 protein level, @entity4 nuclear translocation, Nef2 transcription capacity, and the downstream protein expression. We further demonstrated that @entity7 activation of @entity4 is likely due to its repression of the @entity4 inhibitor @entity6 since it drastically reduced @entity6 protein through the PKC-sensitive ubiquitination-proteasomal degradation. @entity7 treatment of @entity0 @entity1 effectively reduced the @entity0 and inflammatory responses, @entity0 , and improved the pathological protein expression in an @entity4 dependent manner. In addition, @entity7 also @entity4 -dependently modulated macrophage M1/M2 polarization and inhibited the IkBa phosphorylation and NF-kB nuclear translocation, hence revealing an important upstream event that contributed to its anti- @entity2 and tissue protection. Taken together our study has identified a novel pathway through which @entity7 exerts its anti- @entity2 and renal protective functions, and provided a molecular basis for @entity7 potential applications in the treatment of kidney and other @entity2 .

title: XXXX activation of @entity4 signaling prevents hyperactive @entity2 and @entity0 in a @entity1 model of @entity0 .

answer: @entity5


abstract: UNASSIGNED: @entity5 is originally derived from medicinal herb and used preferentially in treatment of @entity3 in Far East regions. @entity7 has strong anti-inflammatory and immune-regulatory properties, acting mainly through inhibiting NF-kB signaling. Although the upstream target through which @entity7 affects NF-kB activity is unknown, evidence suggests that @entity7 might regulate @entity2 through @entity4 signaling. In this study we explored the role of @entity4 in mediating @entity7 's anti- @entity2 and kidney protection in a @entity1 model of @entity0 . We found that @entity7 is an activator of @entity4 signaling. It markedly increased @entity4 protein level, @entity4 nuclear translocation, Nef2 transcription capacity, and the downstream protein expression. We further demonstrated that @entity7 activation of @entity4 is likely due to its repression of the @entity4 inhibitor @entity6 since it drastically reduced @entity6 protein through the PKC-sensitive ubiquitination-proteasomal degradation. @entity7 treatment of @entity0 @entity1 effectively reduced the @entity0 and inflammatory responses, @entity0 , and improved the pathological protein expression in an @entity4 dependent manner. In addition, @entity7 also @entity4 -dependently modulated macrophage M1/M2 polarization and inhibited the IkBa phosphorylation and NF-kB nuclear translocation, hence revealing an important upstream event that contributed to its anti- @entity2 and tissue protection. Taken together our study has identified a novel pathway through which @entity7 exerts its anti- @entity2 and renal protective functions, and provided a molecular basis for @entity7 potential applications in the treatment of kidney and other @entity2 .

title: @entity5 activation of @entity4 signaling prevents hyperactive XXXX and @entity0 in a @entity1 model of @entity0 .

answer: @entity2


abstract: UNASSIGNED: @entity5 is originally derived from medicinal herb and used preferentially in treatment of @entity3 in Far East regions. @entity7 has strong anti-inflammatory and immune-regulatory properties, acting mainly through inhibiting NF-kB signaling. Although the upstream target through which @entity7 affects NF-kB activity is unknown, evidence suggests that @entity7 might regulate @entity2 through @entity4 signaling. In this study we explored the role of @entity4 in mediating @entity7 's anti- @entity2 and kidney protection in a @entity1 model of @entity0 . We found that @entity7 is an activator of @entity4 signaling. It markedly increased @entity4 protein level, @entity4 nuclear translocation, Nef2 transcription capacity, and the downstream protein expression. We further demonstrated that @entity7 activation of @entity4 is likely due to its repression of the @entity4 inhibitor @entity6 since it drastically reduced @entity6 protein through the PKC-sensitive ubiquitination-proteasomal degradation. @entity7 treatment of @entity0 @entity1 effectively reduced the @entity0 and inflammatory responses, @entity0 , and improved the pathological protein expression in an @entity4 dependent manner. In addition, @entity7 also @entity4 -dependently modulated macrophage M1/M2 polarization and inhibited the IkBa phosphorylation and NF-kB nuclear translocation, hence revealing an important upstream event that contributed to its anti- @entity2 and tissue protection. Taken together our study has identified a novel pathway through which @entity7 exerts its anti- @entity2 and renal protective functions, and provided a molecular basis for @entity7 potential applications in the treatment of kidney and other @entity2 .

title: @entity5 activation of XXXX signaling prevents hyperactive @entity2 and @entity0 in a @entity1 model of @entity0 .

answer: @entity4


abstract: UNASSIGNED: @entity5 is originally derived from medicinal herb and used preferentially in treatment of @entity3 in Far East regions. @entity7 has strong anti-inflammatory and immune-regulatory properties, acting mainly through inhibiting NF-kB signaling. Although the upstream target through which @entity7 affects NF-kB activity is unknown, evidence suggests that @entity7 might regulate @entity2 through @entity4 signaling. In this study we explored the role of @entity4 in mediating @entity7 's anti- @entity2 and kidney protection in a @entity1 model of @entity0 . We found that @entity7 is an activator of @entity4 signaling. It markedly increased @entity4 protein level, @entity4 nuclear translocation, Nef2 transcription capacity, and the downstream protein expression. We further demonstrated that @entity7 activation of @entity4 is likely due to its repression of the @entity4 inhibitor @entity6 since it drastically reduced @entity6 protein through the PKC-sensitive ubiquitination-proteasomal degradation. @entity7 treatment of @entity0 @entity1 effectively reduced the @entity0 and inflammatory responses, @entity0 , and improved the pathological protein expression in an @entity4 dependent manner. In addition, @entity7 also @entity4 -dependently modulated macrophage M1/M2 polarization and inhibited the IkBa phosphorylation and NF-kB nuclear translocation, hence revealing an important upstream event that contributed to its anti- @entity2 and tissue protection. Taken together our study has identified a novel pathway through which @entity7 exerts its anti- @entity2 and renal protective functions, and provided a molecular basis for @entity7 potential applications in the treatment of kidney and other @entity2 .

title: @entity5 activation of @entity4 signaling prevents hyperactive @entity2 and @entity0 in a XXXX model of @entity0 .

answer: @entity1


abstract: OBJECTIVE: To evaluate the psychopathological symptoms, suicide, and self-harming behaviors among students with early, on-time, and late menarche in high school and college and the association of early menarche with these disorders. METHODS: The design consisted of a cross-sectional study of 5597 high school students and 2768 college students. Menarche age, suboptimal mental health status, @entity2 , @entity3 , suicide, and self-harming behaviors were obtained by self-report questionnaire. RESULTS: In high school students, all the disorders occurred at significantly higher frequency in those with early menarche than in those with on-time and late menarche. In college students, only suboptimal mental health status, @entity3 , and suicidal ideation happened at significantly higher frequency in the early menarche group than in the other two groups. The college group had a lower frequency of all the disorders than the high school group for all three groups of @entity0 , that is, with early, on-time, or late menarche. In a multivariate logistic regression model, early menarche persisted as a risk factor for all the disorders after other factors were controlled. CONCLUSIONS: Psychopathological symptoms, suicide, and self-harming behaviors are more common in early menarche students than in on-time and late menarche students. The effects of early @entity1 might dissipate over time. Early menarche might serve as a predictor for the disorders in Chinese @entity0 .

title: Early menarche and psychopathological symptoms in young Chinese XXXX .

answer: @entity0


abstract: PURPOSE: To investigate the prevalence of @entity8 ( @entity8 ) among Turkish @entity0 with @entity3 . MATERIALS AND METHODS: Records of 352 eyes of 352 @entity0 who underwent @entity3 surgery were analyzed in this retrospective study. The presence of @entity8 , type of @entity3 , intraocular pressure (IOP), @entity6 , age-related @entity7 , and @entity4 ( @entity5 , @entity2 , @entity1 ) were recorded. RESULTS: The overall prevalence of @entity8 syndrome was detected to be 11%. The mean age of @entity8 @entity0 was significantly higher than without @entity8 (74.4        7.2 years and 69.3        11.4 years, respectively, p   =   0.004). The most common @entity3 type in the @entity8 @entity0 was mixed-type @entity3 determined in 51.2% of @entity0 . IOP was significantly higher in eyes with @entity8 than in eyes without it (16.1        4.5   mmHg and 14.7        3.8   mmHg, respectively; p   =   0.03). Moreover, the prevalence of age-related @entity7 was found to be significantly higher, and prevalence of @entity6 slightly higher in @entity8 @entity0 than without @entity8 . CONCLUSION: @entity8 is a common condition in Turkish @entity0 . @entity8 is associated with mixed type of @entity3 , age-related @entity7 , and elevated IOP. Therefore, @entity8 @entity0 should be checked for concomitant diseases.

title: Prevalence of Pseudoexfoliation Syndrome in Turkish @entity0 with XXXX .

answer: @entity3


abstract: PURPOSE: To investigate the prevalence of @entity8 ( @entity8 ) among Turkish @entity0 with @entity3 . MATERIALS AND METHODS: Records of 352 eyes of 352 @entity0 who underwent @entity3 surgery were analyzed in this retrospective study. The presence of @entity8 , type of @entity3 , intraocular pressure (IOP), @entity6 , age-related @entity7 , and @entity4 ( @entity5 , @entity2 , @entity1 ) were recorded. RESULTS: The overall prevalence of @entity8 syndrome was detected to be 11%. The mean age of @entity8 @entity0 was significantly higher than without @entity8 (74.4        7.2 years and 69.3        11.4 years, respectively, p   =   0.004). The most common @entity3 type in the @entity8 @entity0 was mixed-type @entity3 determined in 51.2% of @entity0 . IOP was significantly higher in eyes with @entity8 than in eyes without it (16.1        4.5   mmHg and 14.7        3.8   mmHg, respectively; p   =   0.03). Moreover, the prevalence of age-related @entity7 was found to be significantly higher, and prevalence of @entity6 slightly higher in @entity8 @entity0 than without @entity8 . CONCLUSION: @entity8 is a common condition in Turkish @entity0 . @entity8 is associated with mixed type of @entity3 , age-related @entity7 , and elevated IOP. Therefore, @entity8 @entity0 should be checked for concomitant diseases.

title: Prevalence of Pseudoexfoliation Syndrome in Turkish XXXX with @entity3 .

answer: @entity0


abstract: UNASSIGNED: The aim of this work is to study whether a quadrupole time-of-flight (QToF) mass analyzer, coupled to an ultra high performance liquid chromatography (UHPLC) system, can be a valuable alternative for a triple-quadrupole (QqQ) mass analyzer, for quantitative toxicological purposes. The case study considered was the quantification of 16 opioids ( @entity13 , @entity6 , @entity8 , @entity9 , @entity7 , @entity5 , @entity2 , @entity10 , @entity1 , @entity12 , @entity16 , @entity15 , @entity3 , @entity11 , @entity17 and @entity14 ) in @entity0 plasma. Both methods were validated in parallel in terms of selectivity, matrix effects, extraction recovery, carry-over, bias, precision and sensitivity. Accuracy-profile methodology was used to determine the optimal calibration model, and to estimate bias, repeatability, intermediate precision and total error. Selectivity was demonstrated for all opioids and deuterated analogues, except for @entity8 -d3 on the UHPLC-QTOF. For most compounds, extraction recoveries were in the range 60 to 80% on both systems, except for the synthetic analogues, @entity6 , @entity5 and @entity14 , where large variability is observed. Carry-over was negligible on both systems. For different opioids, the optimal calibration model was different between the systems. The accuracy profiles of the majority of the opioids indicated that, over the entire tested concentration range, for more than 5% of the future measurements, total errors are expected to exceed the a priori defined 15% acceptance limit. For some exceptions, however, the measurements even suffer from @entity4 30%, which can be attributed to the solid phase extraction procedure that was applied as sample pretreatment technique. Sensitivity was generally tenfold better on the LC-QToF system, probably due to the difference in ion choice for quantification between both systems. In conclusion, the best performing system seemed to depend on the compound, on the parameter and even on the concentration. Accuracy profiles clearly provided valuable information complementary to that obtained in classical validation tests, and therefore preferably are taken into account when deciding on a method's performance.

title: Comparison of a triple-quadrupole and a quadrupole time-of-flight mass analyzer to quantify 16 opioids in XXXX plasma.

answer: @entity0


abstract: We evaluated intravenous streptokinase in the treatment of @entity4 . Following neurological assessment and cerebral computed tomography (CT), @entity0 aged 40-80 years with symptoms of anterior circulation acute @entity2 were given 1.5 M units streptokinase or saline placebo in a double-blind randomized study. Twenty @entity0 (10 streptokinase, 10 placebo), 11 males, 9 females, aged 57-79 years, were treated out of 512 consecutive admissions to the @entity2 unit over a 2-year period. Initial CT was normal in 11 (6 placebo, 5 streptokinase) and showed early signs of @entity4 in nine (4 placebo, 5 streptokinase). Median times from symptom onset to treatment were 5.2 h (placebo) and 5.8 h (streptokinase). Streptokinase treatment was associated with symptomatic @entity5 in one @entity0 . Repeat CT at 72 h demonstrated @entity6 in two @entity0 and @entity6 in one @entity0 in the streptokinase group; the two cases of haematoma formation were associated with @entity1 and @entity3 . One @entity0 in the placebo group had evidence of @entity6 at 72 h. There were three deaths in each treatment group, all within the first 14 days. @entity0 with @entity2 can be evaluated with CT and treated with streptokinase within 6 h, but the opportunity for treatment is currently limited to few @entity0 . Streptokinase treatment is not without risk, but potential clinical benefit justifies ongoing multicentre randomized trials.

title: A pilot study of streptokinase for acute XXXX .

answer: @entity4


abstract: OBJECTIVE: To examine the long-term outcome of early abduction splinting versus active sonographic surveillance in newborns with mildly @entity1 . @entity0 AND METHODS: Between 1997 and 2003, 128 newborns with mildly @entity4 and potentially unstable hips on ultrasound (43    <= a-angle < 50  ) were randomly assigned to immediate abduction treatment or sonographic surveillance. All were invited for a radiographic follow-up at 6 years. The radiographs were analyzed by a single radiologist masked to the randomization allocation, and markers of @entity1 (acetabular index, center-edge angle of Wiberg) and @entity3 were reported. RESULTS: Eighty-three @entity0 (65%) agreed to participate in the follow-up (42 @entity0 from the treatment group). The mean acetabular index was 14.7   (SD: 5.6  ) for the treatment group and 13.9   (SD: 3.9  ) for the control group (mean difference: -0.8   [95% confidence interval: -2.9   to 1.3  ]). Values were within normal ranges for age for all @entity0 except for 1 female subject from the treatment group. The mean center edge was 26.6   for those treated and 26.4   for the active surveillance group (mean difference: -0.3   [95% confidence interval: -2.5   to 2.0  ]). None had markers suggestive of @entity3 . CONCLUSIONS: We found no difference in radiographic outcome at 6 years of age between @entity0 allocated to initial splintage for 6 weeks and those offered active sonographic surveillance. The delayed acetabular ossification or persistent @entity2 seen in a third of @entity0 from both groups at 1 year of age had completely resolved in all but 1 of the female subjects from the treatment group.

title: Newborns with sonographically XXXX and potentially unstable hips: 6-year follow-up of an RCT.

answer: @entity4


abstract: OBJECTIVES: The @entity2 /node/ @entity1 (TNM) staging system for @entity4 ( @entity4 ) is a worldwide standard, but has many limitations. @entity2 volume has been suggested as a predictor of survival. Due to the complex anatomy, estimation of @entity2 volume via CT scan can be challenging. Surgical volume may be more accurate. Therefore, we prospectively determined resected specimen volumes and weights in consecutive @entity0 undergoing extended pleurectomy and decortication (EPD) and correlated this with overall survival and T and N stage. METHODS: We evaluated 116 @entity0 undergoing EPD for @entity4 in a single university centre over a 6-year period. All resected specimens were weighed, and the volume was measured by a fluid displacement method. A Cox regression model was used to identify significant predictors of survival; hazard ratios were calculated. A Kaplan-Meier method was used to summarize overall and subgroup survival. @entity3 models were used to identify predictors of T and N stage. RESULTS: There were 95 males and 21 females with a median age of 68 range 43-88 years. Forty-one @entity0 had an ECOG performance status (PS) 0, 70 had 1 and 4 had 2. The median time between initial diagnosis and surgery was 134 days. Histology was epithelioid in 59, biphasic in 55 and sarcomatoid in 2. The mean volume was 641 ml with an SD of 393.34 ml. The median volume was 567.5 ml. The mean weight was 620.8 g with an SD of 361.92 g. The median weight was 552.0 g. Two-year survival from initial diagnosis and from EPD was 44 and 28%, respectively. PS (P = 0.002), epithelioid histology (P < 0.001), specimen weight (P < 0.001), volume (P < 0.001), platelet count (P = 0.015), T1 stage (P = 0.04) and adjuvant therapy (P = 01) were predictive of survival. @entity2 volume was a predictor of T stage (P = 0.048) and survival (P = 0.03). There was no relationship between N stage and @entity2 volume, weight or histology. CONCLUSIONS: PS, specimen weight, volume, epithelioid histology platelet count and adjuvant chemotherapy are significant predictors of survival in @entity0 undergoing EPD for @entity4 . There is a correlation between specimen volume and T stage. These data suggest that @entity2 weight and volume may be valuable components for staging @entity4 .

title: Specimen weight and volume: important predictors of survival in XXXX   .

answer: @entity4


abstract: UNASSIGNED: Population-based studies on contact @entity0 to @entity1 ( @entity2 ) are scarce. A cross-sectional study was performed to assess the prevalence of contact @entity0 to @entity2 and its risk factors in the general population of 5 European countries. A total of 10,425 subjects were interviewed, and a random sample (n  = 2,739) was patch tested to @entity2 . Overall, 5,286 individuals (50.9%) reported having used hair colorants at least once in their lifetime (78% female, 20% male), and 35% had used hair colorants during the last 12 months. Hair colorant avoidance because of any skin problem during the lifetime was reported by 6%. Black henna tattoos had been used by 5.5% during their lifetime. The prevalence of @entity2 contact @entity0 was 0.8% (95% confidence interval 0.6-1.0%), with no statistically significant association with gender or hair dye use. The prevalence of @entity2 in black henna tattoo users was 3.2% versus 0.6% in nonusers (P < 0.001). A clinically relevant positive patch test reaction to @entity2 related to hair coloring products was found in 0.1% (95% confidence interval 0.0-0.2%). A significant association with @entity2 contact @entity0 was observed for subjects who had black henna tattoos in their lifetime, with an age- and gender-adjusted odds ratio of 9.33 (95% confidence interval 3.45-25.26, P < 0.001). Black henna tattoos are an important risk factor for @entity2 contact @entity0 .

title: Prevalence of Contact Allergy to XXXX in the European General Population.

answer: @entity1


abstract: BACKGROUND: Use of the forearm basilic vein for the creation of an @entity2 has been codified as second-choice vascular access for hemodialysis in the last clinical guidelines of the Society for Vascular Surgery in 2008. Poor literature data on this technical option and on its evaluation and outcomes led us to initiate a retrospective single-center study. METHODS: We analyzed the outcomes of every @entity2 using the forearm basilic vein created in our department. It is a retrospective study in which we collected data prospectively by contacting dialysis centers, nephrologists, and @entity0 . Primary end point was primary patency rate at 1 year. Secondary end points were secondary patency rate at 1 year, time of maturation, and Doppler flow measurement before the first puncture. RESULTS: From February 2004 to June 2014, 49 forearm basilic arteriovenous fistulas were created: 33 ulnar-basilic and 16 radial basilic arteriovenous fistulas. Initial technical success rate was 98%. Functional success rate was 60%. Primary and secondary patency rates at 1 year were respectively 21% and 48%. Median time of maturation was 81  days, and mean Doppler flow measurement was 678  mL/min. @entity1 had a statistically significant shorter time of maturation than radial basilic fistulas (P  <= 0.05). CONCLUSIONS: Despite poor primary patency rate and a long time of maturation, forearm basilic @entity2 has satisfactory secondary patency rate and keeps all the advantages of a distal-located vascular access concerning complications. It is worth its second-choice place in the current algorithm of creation of vascular access for hemodialysis.

title: Promising Results of the Forearm Basilic XXXX Reveal a Worthwhile Option between Radial Cephalic and Brachial @entity1 .

answer: @entity1


abstract: BACKGROUND: Use of the forearm basilic vein for the creation of an @entity2 has been codified as second-choice vascular access for hemodialysis in the last clinical guidelines of the Society for Vascular Surgery in 2008. Poor literature data on this technical option and on its evaluation and outcomes led us to initiate a retrospective single-center study. METHODS: We analyzed the outcomes of every @entity2 using the forearm basilic vein created in our department. It is a retrospective study in which we collected data prospectively by contacting dialysis centers, nephrologists, and @entity0 . Primary end point was primary patency rate at 1 year. Secondary end points were secondary patency rate at 1 year, time of maturation, and Doppler flow measurement before the first puncture. RESULTS: From February 2004 to June 2014, 49 forearm basilic arteriovenous fistulas were created: 33 ulnar-basilic and 16 radial basilic arteriovenous fistulas. Initial technical success rate was 98%. Functional success rate was 60%. Primary and secondary patency rates at 1 year were respectively 21% and 48%. Median time of maturation was 81  days, and mean Doppler flow measurement was 678  mL/min. @entity1 had a statistically significant shorter time of maturation than radial basilic fistulas (P  <= 0.05). CONCLUSIONS: Despite poor primary patency rate and a long time of maturation, forearm basilic @entity2 has satisfactory secondary patency rate and keeps all the advantages of a distal-located vascular access concerning complications. It is worth its second-choice place in the current algorithm of creation of vascular access for hemodialysis.

title: Promising Results of the Forearm Basilic @entity1 Reveal a Worthwhile Option between Radial Cephalic and Brachial XXXX .

answer: @entity1


abstract: UNASSIGNED: This study evaluated whether toddlers in an extended preventive program of semiannual @entity1 varnish applications from 1 year of age had a lower incidence of @entity2 than those undergoing a standard program. A cohort of 1-year-old @entity0 (n = 3,403) living in multicultural areas of low socioeconomic standing in Stockholm participated in a cluster-randomized controlled field trial with two parallel arms. The @entity0 attended 23 dental clinics. Using the ICDAS II criteria, the examiners recorded @entity2 at baseline and after 1 and 2 years. The @entity0 in the reference group received a standardized oral health program once yearly between 1 and 3 years of age. The @entity0 in the test group received the same standard program supplemented with topical applications of @entity1 varnish every 6 months. We compared the test group and the reference group for the prevalence and @entity2 . At baseline, 5% of the @entity0 had already developed @entity2 (ICDAS II 1-6). We reexamined the @entity0 after 1 year (n = 2,675) and after 2 years (n = 2,536). Neither prevalence nor @entity2 increment differed between the groups. At 3 years of age, 12% of the @entity0 had developed moderate and severe @entity2 (ICDAS II 3-6), with a mean increment of 0.5 (SD 2.4) in the test group and 0.6 (SD 2.2) in the reference group. In conclusion, semiannual professional applications of @entity1 varnish, as a supplement to a standard oral health program, failed to reduce @entity2 development in toddlers from high-risk communities.

title: Effectiveness of Early Preventive Intervention with Semiannual XXXX Varnish Application in Toddlers Living in High-Risk Areas: A Stratified Cluster-Randomized Controlled Trial.

answer: @entity1


abstract: OBJECTIVE:     To conduct a preclinical evaluation of the ability of natural killer cells to cytolyze @entity2 cells that were modified to show enhanced expression of @entity5 ( @entity5 ) ligands by R8-liposome-bacillus Calmette-Gu  in (BCG)-cell wall skeleton (CWS) treatment. MATERIALS AND METHODS:     The @entity0 cells and @entity0 cells were co-cultured with R8-liposome-BCG-CWS and BCG for 2, 4, or 6 h, and then the surface expression of @entity5 ligands was analyzed using TaqMan real-time quantitative RT-PCR.     Peripheral blood mononuclear cells were obtained with a conventional preparation kit, and then lymphokine-activated killer (LAK) cells were generated from these purified peripheral blood mononuclear cells via @entity3 stimulation.     The anti- @entity1 effect of LAK cells against untreated and R8-liposome-BCG-CWS co-cultured with cells of the @entity0 @entity2 cell lines T24 and RT-112 was analyzed using the cytotoxic WST-8 assay method at 4 h of culture at various effector/target (E : T) ratios. RESULTS:     Major histocompatibility complex class I-related chain B ( @entity4 ) expression was increased    1.5-fold on @entity0 cells and @entity0 cells with BCG.     @entity7 expression was also increased    1.5-fold on @entity0 cells and @entity0 cells with BCG. R8-liposome-BCG-CWS increased the surface expression of @entity4 2.2-fold on @entity0 cells but did not increase it significantly on @entity0 cells.     @entity7 expression was increased    2.2-fold on @entity0 cells, although no differences were observed between the expression of @entity6 and 3 with R8-liposome-BCG-CWS.     @entity0 cells that were co-cultured with R8-liposome-BCG-CWS showed an    1.3-fold increase in sensitivity to cytolysis by LAK cells at an E : T ratio of 4 and @entity0 cells showed an    1.4-fold increase at an E : T ratio of 2. CONCLUSIONS:     In the present study, the induction of surface @entity5 ligands by R8-liposome-BCG-CWS rendered @entity1 cells more susceptible to cytolysis by LAK cells.     @entity0 cells and @entity0 cells, even when cultured singly in the absence of immune cells, can directly respond to R8-liposome-BCG-CWS.     The results obtained in the present study may therefore indicate a novel adoptive immunotherapy against @entity2 .

title: The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu  in can directly enhance the susceptibility of @entity1 cells to lymphokine-activated killer cells through up-regulation of XXXX ligands.

answer: @entity5


abstract: OBJECTIVE:     To conduct a preclinical evaluation of the ability of natural killer cells to cytolyze @entity2 cells that were modified to show enhanced expression of @entity5 ( @entity5 ) ligands by R8-liposome-bacillus Calmette-Gu  in (BCG)-cell wall skeleton (CWS) treatment. MATERIALS AND METHODS:     The @entity0 cells and @entity0 cells were co-cultured with R8-liposome-BCG-CWS and BCG for 2, 4, or 6 h, and then the surface expression of @entity5 ligands was analyzed using TaqMan real-time quantitative RT-PCR.     Peripheral blood mononuclear cells were obtained with a conventional preparation kit, and then lymphokine-activated killer (LAK) cells were generated from these purified peripheral blood mononuclear cells via @entity3 stimulation.     The anti- @entity1 effect of LAK cells against untreated and R8-liposome-BCG-CWS co-cultured with cells of the @entity0 @entity2 cell lines T24 and RT-112 was analyzed using the cytotoxic WST-8 assay method at 4 h of culture at various effector/target (E : T) ratios. RESULTS:     Major histocompatibility complex class I-related chain B ( @entity4 ) expression was increased    1.5-fold on @entity0 cells and @entity0 cells with BCG.     @entity7 expression was also increased    1.5-fold on @entity0 cells and @entity0 cells with BCG. R8-liposome-BCG-CWS increased the surface expression of @entity4 2.2-fold on @entity0 cells but did not increase it significantly on @entity0 cells.     @entity7 expression was increased    2.2-fold on @entity0 cells, although no differences were observed between the expression of @entity6 and 3 with R8-liposome-BCG-CWS.     @entity0 cells that were co-cultured with R8-liposome-BCG-CWS showed an    1.3-fold increase in sensitivity to cytolysis by LAK cells at an E : T ratio of 4 and @entity0 cells showed an    1.4-fold increase at an E : T ratio of 2. CONCLUSIONS:     In the present study, the induction of surface @entity5 ligands by R8-liposome-BCG-CWS rendered @entity1 cells more susceptible to cytolysis by LAK cells.     @entity0 cells and @entity0 cells, even when cultured singly in the absence of immune cells, can directly respond to R8-liposome-BCG-CWS.     The results obtained in the present study may therefore indicate a novel adoptive immunotherapy against @entity2 .

title: The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Gu  in can directly enhance the susceptibility of XXXX cells to lymphokine-activated killer cells through up-regulation of @entity5 ligands.

answer: @entity1


abstract: Two local blood flow regulating mechanisms were studied before and after arterial reconstruction in 30 limbs suffering from @entity2 . Changes in forefoot blood flow were measured from the washout of a subcutaneous 133xenon depot. Arterial and venous pressures were changed by passive lowering and elevation of the foot. In 14 limbs suffering from severe @entity1 , the local vasoconstrictor response to increased venous pressure was abolished as blood flow increased 37% when the limbs were lowered 40 cm. Autoregulation of blood flow was abolished also as flow decreased 51% when the limbs were elevated 20 cm. The estimated vascular resistance was constant during lowering and elevation, indicating paralysis of the arterioles. The vasoconstrictor response had returned at the tenth postoperative day as blood flow decreased 32% during lowering. Autoregulation had also returned as blood flow remained almost constant during elevation to 40 cm. In 16 limbs with less severe @entity1 , vasoconstrictor response as well as autoregulation was preserved before operation, and no disturbances occurred after operation. Despite the early normalization of local blood flow regulation, postoperative @entity3 developed in most limbs. Post-reconstruction @entity0 developed after all but one of the 13 femorodistal bypass operations and after only one of the 17 aortoiliac reconstructions. This suggests that post-reconstruction @entity3 and post-reconstruction @entity0 are not caused by @entity4 .

title: Normalization of local blood flow regulation in the XXXX forefoot after arterial reconstruction.

answer: @entity1


abstract: Both, common gene variants and @entity0 adenovirus 36 (Adv36) are involved in the pathogenesis of @entity1 . The potential relationship between these two pathogenic factors has not yet been investigated. The aim of our study was to examine the association of @entity1 susceptibility loci with Adv36 status. Genotyping of ten gene variants (in/near @entity7 , @entity8 , @entity11 , @entity5 , @entity3 , @entity10 , @entity2 , @entity6 ) and analysis of Adv36 antibodies was performed in 1,027 Czech adolescents aged 13.0-17.9 years. Variants of two genes ( @entity5 and @entity3 ) were associated with Adv36 seropositivity. A higher prevalence of Adv36 antibody positivity was observed in @entity1 risk allele carriers of @entity5 @entity13 , @entity9 and @entity3 @entity14 vs. non-carriers (chi(2)=6.59, p=0.010; chi(2)=7.56, p=0.023 and chi(2)=6.84, p=0.033, respectively). The increased risk of Adv36 positivity was also found in @entity5 variants: @entity13 (OR=1.67, 95 % CI 1.11-2.49, p=0.016) and @entity9 (OR=1.34, 95 % CI 1.08-1.67, p=0.010). @entity5 @entity13 and @entity3 @entity12 variants were closely associated with Adv36 status in @entity0 and @entity0 , respectively (chi(2)=5.09, p=0.024; chi(2)=7.29, p=0.026). Furthermore, @entity5 @entity9 risk allele was related to Adv36 seropositivity (chi(2)=6.85, p=0.033) in overweight/ @entity1 subgroup. In conclusion, our results suggest that @entity1 risk variants of @entity5 and @entity3 genes may be related to @entity4 .

title: Association of adenovirus 36 infection with XXXX -related gene variants in adolescents.

answer: @entity1


abstract: Unexplained @entity2 is the main indication for the implantation of a diagnostic pacemaker. Studies on those implanted have shown that in @entity0 with unexplained @entity2 , the diagnosis of paroxysmal @entity3 was feasible and reliable. The present study was designed to evaluate a new @entity3 diagnosis algorithm, loaded in a dual chamber pacemaker, in 24 @entity0 considered as candidates for diagnostic pacemakers. During a mean follow-up of 153 days, at least one @entity3 episode was recorded in 13 @entity0 . The mean number of detected @entity3 was 6 and the median was 3. The mean delay between the algorithm activation and the first @entity3 episode was 67 days. The mechanism of @entity3 was @entity1 in 6 @entity0 , @entity4 in 6 @entity0 , and consecutive blocked atrial premature beats in 1 @entity0 , as indicated by the event markers. In 11 @entity0 @entity3 was recorded during the daytime only or day and night. In two @entity0 the episodes were recorded only at night. Overall, the algorithm was well-tolerated; however, some mild symptoms were observed due to the method of @entity3 determination, allowing @entity3 . Three @entity0 were symptomatic as a direct result of the algorithm operation, and four @entity0 had symptoms related to the single chamber operation of the pacemaker while functioning in the diagnosis mode (VDI). These symptoms were relieved with @entity5 pacing.

title: Preliminary evaluation of a dual chamber pacemaker with XXXX diagnostic functions.

answer: @entity3


abstract: @entity3 (NE) causes extensive @entity2 in the @entity1 . To investigate a potential mechanism we measured coronary blood flow with radioactive microspheres. Coronary resistance and @entity0 demand (heart rate-blood pressure double product) were calculated. Severity of injury was determined by semiquantitative histologic evaluation. Changes resulting from NE infusion were determined in animals with or without alpha-receptor blockade with @entity4 (10 mg). In all animals @entity0 demand remained constant. Coronary blood flow (ml/gm/min) was 2.66 at the beginning of the experiment, rose to 3.46 after 3 minutes of NE infusion (p less than 0.05), then declined to baseline values (2.33) after 10 minutes. However, coronary blood flow was sharply lower than baseline (1.51; p less than 0.05) after 40 minutes of infusion. Coronary resistance rose progressively from baseline values of 40.9 (units) to 74.8 at 40 minutes (p less than 0.05). Animals given @entity4 manifested none of these changes. Control subjects infused with saline solution showed no significant changes in coronary blood flow or coronary resistance. Animals pretreated with @entity4 had minimal histologic damage at 48 hours compared with NE alone (p less than 0.01). We conclude that NE induces sustained coronary vasoconstriction in the @entity1 and that reduced coronary blood flow may contribute to the pathogenesis of NE @entity2 in this species.

title: Coronary vasoconstriction and catecholamine XXXX .

answer: @entity2


abstract: PURPOSE: The prognosis of @entity4 ( @entity4 ) is disappointing for @entity0 who experience primary treatment failure or relapse after an initial response. @entity0 in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of @entity0 with relapsed or @entity4 . MATERIAL AND METHODS: Forty-three pretreated @entity0 with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most @entity0 (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of @entity0 had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) @entity0 had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. @entity3 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. @entity5 8 mg/m2 was administered as a short IV infusion on day 1. @entity6 (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per @entity0 (range, 1-8). The mean relative dose intensity was 87.4%. RESULTS: 1) Nine @entity0 achieved a complete response and nine @entity0 achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable @entity0 . 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of @entity1 of MINE was @entity2 . CONCLUSION: The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.

title: MINE (mesna, @entity3 , XXXX , @entity6 ) Chemotherapy as a Treatment of Relapsed or Refractory Aggressive @entity4 .

answer: @entity5


abstract: PURPOSE: The prognosis of @entity4 ( @entity4 ) is disappointing for @entity0 who experience primary treatment failure or relapse after an initial response. @entity0 in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of @entity0 with relapsed or @entity4 . MATERIAL AND METHODS: Forty-three pretreated @entity0 with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most @entity0 (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of @entity0 had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) @entity0 had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. @entity3 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. @entity5 8 mg/m2 was administered as a short IV infusion on day 1. @entity6 (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per @entity0 (range, 1-8). The mean relative dose intensity was 87.4%. RESULTS: 1) Nine @entity0 achieved a complete response and nine @entity0 achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable @entity0 . 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of @entity1 of MINE was @entity2 . CONCLUSION: The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.

title: MINE (mesna, XXXX , @entity5 , @entity6 ) Chemotherapy as a Treatment of Relapsed or Refractory Aggressive @entity4 .

answer: @entity3


abstract: PURPOSE: The prognosis of @entity4 ( @entity4 ) is disappointing for @entity0 who experience primary treatment failure or relapse after an initial response. @entity0 in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of @entity0 with relapsed or @entity4 . MATERIAL AND METHODS: Forty-three pretreated @entity0 with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most @entity0 (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of @entity0 had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) @entity0 had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. @entity3 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. @entity5 8 mg/m2 was administered as a short IV infusion on day 1. @entity6 (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per @entity0 (range, 1-8). The mean relative dose intensity was 87.4%. RESULTS: 1) Nine @entity0 achieved a complete response and nine @entity0 achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable @entity0 . 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of @entity1 of MINE was @entity2 . CONCLUSION: The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.

title: MINE (mesna, @entity3 , @entity5 , XXXX ) Chemotherapy as a Treatment of Relapsed or Refractory Aggressive @entity4 .

answer: @entity6


abstract: PURPOSE: The prognosis of @entity4 ( @entity4 ) is disappointing for @entity0 who experience primary treatment failure or relapse after an initial response. @entity0 in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of @entity0 with relapsed or @entity4 . MATERIAL AND METHODS: Forty-three pretreated @entity0 with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most @entity0 (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of @entity0 had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) @entity0 had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. @entity3 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. @entity5 8 mg/m2 was administered as a short IV infusion on day 1. @entity6 (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per @entity0 (range, 1-8). The mean relative dose intensity was 87.4%. RESULTS: 1) Nine @entity0 achieved a complete response and nine @entity0 achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable @entity0 . 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of @entity1 of MINE was @entity2 . CONCLUSION: The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.

title: MINE (mesna, @entity3 , @entity5 , @entity6 ) Chemotherapy as a Treatment of Relapsed or Refractory Aggressive XXXX .

answer: @entity4


abstract: PURPOSE: There are few therapeutic options in @entity0 with @entity1 that have progressed or recurred following @entity11 ( @entity11 ) based therapy. We evaluated the efficacy and @entity3 of @entity9 , @entity11 , @entity12 (Mayo clinic regimen) in @entity11 pretreated advanced @entity1 @entity0 . MATERIALS AND METGODS: Twenty-eight @entity0 were enrolled in this study between January 1999 and May 2001. @entity0 were treated with @entity9 150 mg/m2 on day 1 as a 2-hr infusion and @entity11 425 mg/m2, @entity12 20 mg/m2, bolus for 5 days. Treatment courses were repeated in 4-week intervals. RESULTS: The objective response rate was 25% for 28 assessable @entity0 , all cases registered a partial response. Eleven @entity0 (39%) demonstrated stable disease, and ten (36%) progressed. The median response duration was 5.5 months, and the median time to progression was 6.3 months. The median overall survival time was 13.5 months from the start of the chemotherapy. From the 120 cycles analyzed, grade 3,4 hematologic @entity3 included @entity10 : 1.6%, and @entity8 : 1.6%. The frequent grade 3.4 non-hematologic adverse reactions were @entity6 / @entity7 (25.0%), @entity5 (14.3%), stomititis (3.6%), and @entity2 (3.6%). There were no treatment-related @entity4 . CONCLUSION: This phase II study had relatively higher @entity3 than previous studies, and did not show an increased significant response rate. These high levels of @entity3 suggest that the study treatment combination of @entity9 with a full dose Mayo clinic regimen arm is no feasible. Therefore, this regimen will be discontinued and a safer regimen will be adopted.

title: A Phase II Study of XXXX Combined with @entity11 and @entity12 (Mayo Clinic Regimen) in @entity11 Refractory @entity1 .

answer: @entity9


abstract: PURPOSE: There are few therapeutic options in @entity0 with @entity1 that have progressed or recurred following @entity11 ( @entity11 ) based therapy. We evaluated the efficacy and @entity3 of @entity9 , @entity11 , @entity12 (Mayo clinic regimen) in @entity11 pretreated advanced @entity1 @entity0 . MATERIALS AND METGODS: Twenty-eight @entity0 were enrolled in this study between January 1999 and May 2001. @entity0 were treated with @entity9 150 mg/m2 on day 1 as a 2-hr infusion and @entity11 425 mg/m2, @entity12 20 mg/m2, bolus for 5 days. Treatment courses were repeated in 4-week intervals. RESULTS: The objective response rate was 25% for 28 assessable @entity0 , all cases registered a partial response. Eleven @entity0 (39%) demonstrated stable disease, and ten (36%) progressed. The median response duration was 5.5 months, and the median time to progression was 6.3 months. The median overall survival time was 13.5 months from the start of the chemotherapy. From the 120 cycles analyzed, grade 3,4 hematologic @entity3 included @entity10 : 1.6%, and @entity8 : 1.6%. The frequent grade 3.4 non-hematologic adverse reactions were @entity6 / @entity7 (25.0%), @entity5 (14.3%), stomititis (3.6%), and @entity2 (3.6%). There were no treatment-related @entity4 . CONCLUSION: This phase II study had relatively higher @entity3 than previous studies, and did not show an increased significant response rate. These high levels of @entity3 suggest that the study treatment combination of @entity9 with a full dose Mayo clinic regimen arm is no feasible. Therefore, this regimen will be discontinued and a safer regimen will be adopted.

title: A Phase II Study of @entity9 Combined with @entity11 and XXXX (Mayo Clinic Regimen) in @entity11 Refractory @entity1 .

answer: @entity12


abstract: PURPOSE: There are few therapeutic options in @entity0 with @entity1 that have progressed or recurred following @entity11 ( @entity11 ) based therapy. We evaluated the efficacy and @entity3 of @entity9 , @entity11 , @entity12 (Mayo clinic regimen) in @entity11 pretreated advanced @entity1 @entity0 . MATERIALS AND METGODS: Twenty-eight @entity0 were enrolled in this study between January 1999 and May 2001. @entity0 were treated with @entity9 150 mg/m2 on day 1 as a 2-hr infusion and @entity11 425 mg/m2, @entity12 20 mg/m2, bolus for 5 days. Treatment courses were repeated in 4-week intervals. RESULTS: The objective response rate was 25% for 28 assessable @entity0 , all cases registered a partial response. Eleven @entity0 (39%) demonstrated stable disease, and ten (36%) progressed. The median response duration was 5.5 months, and the median time to progression was 6.3 months. The median overall survival time was 13.5 months from the start of the chemotherapy. From the 120 cycles analyzed, grade 3,4 hematologic @entity3 included @entity10 : 1.6%, and @entity8 : 1.6%. The frequent grade 3.4 non-hematologic adverse reactions were @entity6 / @entity7 (25.0%), @entity5 (14.3%), stomititis (3.6%), and @entity2 (3.6%). There were no treatment-related @entity4 . CONCLUSION: This phase II study had relatively higher @entity3 than previous studies, and did not show an increased significant response rate. These high levels of @entity3 suggest that the study treatment combination of @entity9 with a full dose Mayo clinic regimen arm is no feasible. Therefore, this regimen will be discontinued and a safer regimen will be adopted.

title: A Phase II Study of @entity9 Combined with @entity11 and @entity12 (Mayo Clinic Regimen) in @entity11 Refractory XXXX .

answer: @entity1


abstract: PURPOSE: There are few therapeutic options in @entity0 with @entity1 that have progressed or recurred following @entity11 ( @entity11 ) based therapy. We evaluated the efficacy and @entity3 of @entity9 , @entity11 , @entity12 (Mayo clinic regimen) in @entity11 pretreated advanced @entity1 @entity0 . MATERIALS AND METGODS: Twenty-eight @entity0 were enrolled in this study between January 1999 and May 2001. @entity0 were treated with @entity9 150 mg/m2 on day 1 as a 2-hr infusion and @entity11 425 mg/m2, @entity12 20 mg/m2, bolus for 5 days. Treatment courses were repeated in 4-week intervals. RESULTS: The objective response rate was 25% for 28 assessable @entity0 , all cases registered a partial response. Eleven @entity0 (39%) demonstrated stable disease, and ten (36%) progressed. The median response duration was 5.5 months, and the median time to progression was 6.3 months. The median overall survival time was 13.5 months from the start of the chemotherapy. From the 120 cycles analyzed, grade 3,4 hematologic @entity3 included @entity10 : 1.6%, and @entity8 : 1.6%. The frequent grade 3.4 non-hematologic adverse reactions were @entity6 / @entity7 (25.0%), @entity5 (14.3%), stomititis (3.6%), and @entity2 (3.6%). There were no treatment-related @entity4 . CONCLUSION: This phase II study had relatively higher @entity3 than previous studies, and did not show an increased significant response rate. These high levels of @entity3 suggest that the study treatment combination of @entity9 with a full dose Mayo clinic regimen arm is no feasible. Therefore, this regimen will be discontinued and a safer regimen will be adopted.

title: A Phase II Study of @entity9 Combined with XXXX and @entity12 (Mayo Clinic Regimen) in @entity11 Refractory @entity1 .

answer: @entity11


abstract: PURPOSE: There are few therapeutic options in @entity0 with @entity1 that have progressed or recurred following @entity11 ( @entity11 ) based therapy. We evaluated the efficacy and @entity3 of @entity9 , @entity11 , @entity12 (Mayo clinic regimen) in @entity11 pretreated advanced @entity1 @entity0 . MATERIALS AND METGODS: Twenty-eight @entity0 were enrolled in this study between January 1999 and May 2001. @entity0 were treated with @entity9 150 mg/m2 on day 1 as a 2-hr infusion and @entity11 425 mg/m2, @entity12 20 mg/m2, bolus for 5 days. Treatment courses were repeated in 4-week intervals. RESULTS: The objective response rate was 25% for 28 assessable @entity0 , all cases registered a partial response. Eleven @entity0 (39%) demonstrated stable disease, and ten (36%) progressed. The median response duration was 5.5 months, and the median time to progression was 6.3 months. The median overall survival time was 13.5 months from the start of the chemotherapy. From the 120 cycles analyzed, grade 3,4 hematologic @entity3 included @entity10 : 1.6%, and @entity8 : 1.6%. The frequent grade 3.4 non-hematologic adverse reactions were @entity6 / @entity7 (25.0%), @entity5 (14.3%), stomititis (3.6%), and @entity2 (3.6%). There were no treatment-related @entity4 . CONCLUSION: This phase II study had relatively higher @entity3 than previous studies, and did not show an increased significant response rate. These high levels of @entity3 suggest that the study treatment combination of @entity9 with a full dose Mayo clinic regimen arm is no feasible. Therefore, this regimen will be discontinued and a safer regimen will be adopted.

title: A Phase II Study of @entity9 Combined with @entity11 and @entity12 (Mayo Clinic Regimen) in XXXX Refractory @entity1 .

answer: @entity11


abstract: PURPOSE: The Philadelphia (Ph) chromosome is a well- known @entity2 in adults with B-lineage @entity1 , and is associated with a poor prognosis. This study compared the clinical manifestations and prognosis in adult Ph-positive and Ph-negative @entity1 @entity0 . MATERIALS AND METHODS: We retrospectively analyzed the clinical records of adult @entity0 newly diagnosed as B-lineage @entity1 , between January 1995 and February 2001. Fifty five @entity0 were included in this study. We divided the @entity0 into Ph-positive and Ph-negative groups. RESULTS: Eighteen of the 55 @entity0 (32.7%) were found to have the Ph chromosome. At initial diagnosis, the Ph-positive @entity0 had higher circulating leukocyte counts, lower platelet counts and had a greater tendency to bleed, than the Ph-negative group. The complete remission rates were 83.3% and 83.8% for the Ph-positive and the Ph-negative groups, respectively. Four of the Ph-positive, and 13 of the Ph-negative, @entity0 underwent allogenic bone marrow transplantation. The median follow-up for the surviving @entity0 was 39.3 months. The three-year survival rates were 10.4% and 51.8% for the Ph-positive and the Ph-negative groups, respectively. The median disease-free survival was 7.7 months for the Ph-positive group, but did not reach the median value in the Ph-negative group. Among the Ph-positive @entity0 , age was the only factor that had an impact on the disease outcome. CONCLUSION: In adult B-lineage @entity1 , the Ph-positive @entity0 had similar complete remission rates to other @entity0 ; however, the remission was of shorter duration, with a higher relapse rate in the Ph-positive @entity0 . More effective treatments are needed to improve the survival of the Ph-positive @entity0 .

title: The Outcome of Philadelphia XXXX : Characteristics and Prognosis.

answer: @entity1


abstract: PURPOSE: Here, our results from a prospective treatment protocol of concurrent radiochemotherapy (CRCT), which was conducted for locally advanced @entity1 , between April 1994 and May 2001, are reported. MATERIALS AND METHODS: A total of 52 consecutive eligible @entity0 were accumulated for this protocol. The median radiation doses to the primary site, involved nodes and uninvolved neck were 72, 61.2 and 45 Gy, using a serial shrinking field technique. The boost techniques were 3-dimensional conformal radiation therapy in 45, intracavitary brachytherapy in 3 and 2-dimensional radiation therapy, with multiple small fields, in 2 @entity0 . Two chemotherapy regimens were used: the first regimen, used in 8 @entity0 during the earlier part of the study duration, consisted of 2 cycles of @entity3 plus @entity4 every 4 weeks, with concurrent radiation therapy, and 4 cycles with the same agents every 4 weeks, adjuvantly; the second regimen, used in 44 @entity0 during the later part, consisted of 3 cycles of @entity3 every 3 weeks, with concurrent radiation therapy and 3 cycles of adjuvant @entity3 plus @entity4 every 3 weeks. RESULTS: The median follow-up period of the survivors was 32 months. The male to female ratio was 36/16, with a median age of 48 years. The stages, according to the new AJCC staging system (1997), were IIb in 6, III in 23, IVa in 14 and IVb in 9 @entity0 . Fifty and 32 @entity0 completed the planned radiation therapy and concurrent chemotherapy, respectively. Two @entity0 died, 1 of @entity2 during the CRCT and the other of @entity5 during the adjuvant chemotherapy. There were 12 failures in 11 @entity0 : 7 locoregional recurrences, 1 within and 6 outside the radiation target volume, and 5 distant metastases. The locoregional control, disease-free survival and overall survival rates were 84.3, 78.8 and 92.8% at 3 years, respectively. CONCLUSION: High dose radiation therapy, coupled with concurrent chemotherapy, was judged a highly effective treatment for locally advanced @entity1 .

title: High Dose Radiation Therapy Concurrent with Chemotherapy in Locally Advanced XXXX .

answer: @entity1


abstract: We retrospectively studied the incidence of @entity1 , @entity8 , @entity3 , and @entity2 in 123 consecutive adult liver transplant recipients (61 @entity0 and 62 @entity0 ) who were alive at least 1 year after transplantation. We also studied the change in these metabolic complications in 61 @entity0 who subsequently were able to be tapered to 5 mg @entity6 per day. One year after transplantation--a point at which almost all @entity0 were on maintenance immunosuppression and had stable graft function--the incidence of @entity1 was 13% and @entity3 was 69.1%. The overall incidence of @entity8 (serum @entity5 > 240 ng/ml) was 31% and was more frequent in @entity0 than in @entity0 (38.7% vs. 23.0%, P < 0.06). The incidence of @entity2 at 1 year was 41.9% in @entity0 and 39.3% in @entity0 . With tapering of @entity6 from 10 mg to 5 mg per day in 61 @entity0 , the mean serum @entity5 decreased from 224.6 +/- 65.2 mg/dl to 203.3 +/- 65.5 mg/dl, P < 0.005. With @entity4 tapering, 8 @entity0 were able to discontinue antihypertensive medications and 4 were able to discontinue insulin treatment for @entity1 . Five @entity0 became @entity2 during the @entity4 -tapering period. No @entity0 developed irreversible rejection with @entity4 tapering and no immunologic graft losses occurred more than a year after transplantation. Nine @entity0 who lived a year subsequently died. Of these, 7 @entity0 were @entity1 and 2 died of @entity7 . We conclude that metabolic complications such as @entity1 , @entity3 , and @entity8 are common later after liver transplantation and that these may contribute to @entity0 morbidity and mortality. In addition, we conclude @entity4 tapering to 5 mg/day does not lead to graft loss and may decrease the incidence and severity of late metabolic complications.

title: Metabolic complications after liver transplantation. @entity1 , XXXX , @entity3 , and @entity2 .

answer: @entity8


abstract: We retrospectively studied the incidence of @entity1 , @entity8 , @entity3 , and @entity2 in 123 consecutive adult liver transplant recipients (61 @entity0 and 62 @entity0 ) who were alive at least 1 year after transplantation. We also studied the change in these metabolic complications in 61 @entity0 who subsequently were able to be tapered to 5 mg @entity6 per day. One year after transplantation--a point at which almost all @entity0 were on maintenance immunosuppression and had stable graft function--the incidence of @entity1 was 13% and @entity3 was 69.1%. The overall incidence of @entity8 (serum @entity5 > 240 ng/ml) was 31% and was more frequent in @entity0 than in @entity0 (38.7% vs. 23.0%, P < 0.06). The incidence of @entity2 at 1 year was 41.9% in @entity0 and 39.3% in @entity0 . With tapering of @entity6 from 10 mg to 5 mg per day in 61 @entity0 , the mean serum @entity5 decreased from 224.6 +/- 65.2 mg/dl to 203.3 +/- 65.5 mg/dl, P < 0.005. With @entity4 tapering, 8 @entity0 were able to discontinue antihypertensive medications and 4 were able to discontinue insulin treatment for @entity1 . Five @entity0 became @entity2 during the @entity4 -tapering period. No @entity0 developed irreversible rejection with @entity4 tapering and no immunologic graft losses occurred more than a year after transplantation. Nine @entity0 who lived a year subsequently died. Of these, 7 @entity0 were @entity1 and 2 died of @entity7 . We conclude that metabolic complications such as @entity1 , @entity3 , and @entity8 are common later after liver transplantation and that these may contribute to @entity0 morbidity and mortality. In addition, we conclude @entity4 tapering to 5 mg/day does not lead to graft loss and may decrease the incidence and severity of late metabolic complications.

title: Metabolic complications after liver transplantation. @entity1 , @entity8 , XXXX , and @entity2 .

answer: @entity3


abstract: We retrospectively studied the incidence of @entity1 , @entity8 , @entity3 , and @entity2 in 123 consecutive adult liver transplant recipients (61 @entity0 and 62 @entity0 ) who were alive at least 1 year after transplantation. We also studied the change in these metabolic complications in 61 @entity0 who subsequently were able to be tapered to 5 mg @entity6 per day. One year after transplantation--a point at which almost all @entity0 were on maintenance immunosuppression and had stable graft function--the incidence of @entity1 was 13% and @entity3 was 69.1%. The overall incidence of @entity8 (serum @entity5 > 240 ng/ml) was 31% and was more frequent in @entity0 than in @entity0 (38.7% vs. 23.0%, P < 0.06). The incidence of @entity2 at 1 year was 41.9% in @entity0 and 39.3% in @entity0 . With tapering of @entity6 from 10 mg to 5 mg per day in 61 @entity0 , the mean serum @entity5 decreased from 224.6 +/- 65.2 mg/dl to 203.3 +/- 65.5 mg/dl, P < 0.005. With @entity4 tapering, 8 @entity0 were able to discontinue antihypertensive medications and 4 were able to discontinue insulin treatment for @entity1 . Five @entity0 became @entity2 during the @entity4 -tapering period. No @entity0 developed irreversible rejection with @entity4 tapering and no immunologic graft losses occurred more than a year after transplantation. Nine @entity0 who lived a year subsequently died. Of these, 7 @entity0 were @entity1 and 2 died of @entity7 . We conclude that metabolic complications such as @entity1 , @entity3 , and @entity8 are common later after liver transplantation and that these may contribute to @entity0 morbidity and mortality. In addition, we conclude @entity4 tapering to 5 mg/day does not lead to graft loss and may decrease the incidence and severity of late metabolic complications.

title: Metabolic complications after liver transplantation. @entity1 , @entity8 , @entity3 , and XXXX .

answer: @entity2


abstract: We retrospectively studied the incidence of @entity1 , @entity8 , @entity3 , and @entity2 in 123 consecutive adult liver transplant recipients (61 @entity0 and 62 @entity0 ) who were alive at least 1 year after transplantation. We also studied the change in these metabolic complications in 61 @entity0 who subsequently were able to be tapered to 5 mg @entity6 per day. One year after transplantation--a point at which almost all @entity0 were on maintenance immunosuppression and had stable graft function--the incidence of @entity1 was 13% and @entity3 was 69.1%. The overall incidence of @entity8 (serum @entity5 > 240 ng/ml) was 31% and was more frequent in @entity0 than in @entity0 (38.7% vs. 23.0%, P < 0.06). The incidence of @entity2 at 1 year was 41.9% in @entity0 and 39.3% in @entity0 . With tapering of @entity6 from 10 mg to 5 mg per day in 61 @entity0 , the mean serum @entity5 decreased from 224.6 +/- 65.2 mg/dl to 203.3 +/- 65.5 mg/dl, P < 0.005. With @entity4 tapering, 8 @entity0 were able to discontinue antihypertensive medications and 4 were able to discontinue insulin treatment for @entity1 . Five @entity0 became @entity2 during the @entity4 -tapering period. No @entity0 developed irreversible rejection with @entity4 tapering and no immunologic graft losses occurred more than a year after transplantation. Nine @entity0 who lived a year subsequently died. Of these, 7 @entity0 were @entity1 and 2 died of @entity7 . We conclude that metabolic complications such as @entity1 , @entity3 , and @entity8 are common later after liver transplantation and that these may contribute to @entity0 morbidity and mortality. In addition, we conclude @entity4 tapering to 5 mg/day does not lead to graft loss and may decrease the incidence and severity of late metabolic complications.

title: Metabolic complications after liver transplantation. XXXX , @entity8 , @entity3 , and @entity2 .

answer: @entity1


abstract: In @entity8 , @entity2 manifests itself as @entity3 , concentric left ventricular (LV) @entity6 , or @entity9 . To determine the impact of renal transplantation on @entity2 , all dialysis @entity0 participating in a long-term cohort study who received a successful renal transplant were followed with echocardiography. The transplanted group comprised 102 of 433 (24%) @entity1 ( @entity1 ) @entity0 . They were significantly younger and, on starting @entity1 therapy, had significantly less @entity5 and @entity4 than the overall @entity1 cohort. During followup, @entity5 developed in only 1 @entity0 and none experienced @entity4 . In the 12% (n = 12) of @entity0 with @entity3 before renal transplant, fractional shortening normalized in all @entity0 , increasing from 21.5 +/- 4.6% to 33.5 +/- 5.6% after transplantation. In the 41% (n = 41) with concentric @entity7 before transplantation, the LV mass index improved from 158 +/- 39 g/m2 to 132 +/- 39 g/m2. @entity9 was present in 32% (n = 32) of @entity0 before transplantation. After transplantation, LV volume fell from 116 +/- 3.1 ml/m2 to 89 +/- 21 ml/m2, and LV mass index in this group fell from 166 +/- 55 g/m2 to 135 +/- 37 g/m2. It was not possible to associate risk factors characteristic of the uremic state with the improvement in cardiac structure and function, although the fall in LV mass was significantly associated with fall in blood pressure. We conclude that correction of the uremic state by renal transplantation leads to normalization of LV contractility in @entity3 , regression of @entity6 in concentric @entity7 , and improvement of cavity volume in @entity9 . The degree of improvement suggests that dialysis @entity0 with @entity2 would benefit from renal transplantation.

title: Impact of renal transplantation on XXXX .

answer: @entity2


abstract: PURPOSE: @entity2 is one of the major causes of @entity3 from @entity1 worldwide. To explore the expressions of global protein in @entity2 cells, a proteomic approach, to identify the proteins, was used and the establishment of a protein reference map attempted. MATERIALS AND METHODS: Two-dimensional gel electrophoresis (2-DE), with subsequent analysis by mass spectrometry (MS), was applied to the study of protein identification from a @entity2 cell line, @entity0 . The cells were lysed, and the extracts subjected to isoelectric focusing, with immobilized pH gradients, followed by second dimension SDS-PAGE. The polypeptides were identified by peptide mass fingerprinting, with @entity4 , after in-gel protein digestion. RESULTS: From @entity5 staining of the gel, around two thousands protein spots were separated by the 2-DE. Of these protein spots visualized in the gel, one hundred and ten were identified by peptide mass fingerprinting. Different proteins, such as enzymes, cytoskeletal proteins and proteins common to eukaryotic cells, were identified. CONCLUSION: The protein expressions of the @entity2 cells were analyzed to establish a protein reference map. The reference map presented here may serve as a working tool for the further study of @entity2 .

title: Proteomic Profiling of XXXX Small Cell Lung Cancer Cell Line NCI-H211.

answer: @entity0


abstract: PURPOSE: Peritoneal seeding is the most common type of @entity1 or recurrence and one of the poor prognostic factors in @entity4 . Moreover, there are as yet no effective treatment modalities available. Recently some research groups suggested the benefit of combined cytoreductive surgery and intraperitoneal chemotherapy, but the related experiments remain in the trial stage. Therefore, we assessed the safety and evaluated the efficacy of combined cytoreductive surgery and early postoperative intraperitoneal chemotherapy (EPIC) in @entity4 @entity0 with @entity3 of @entity4 . MATERIALS AND METHODS: From Nov. 1997 to May. 2002, eighteen cases of combined cytoreduction and EPIC were performed in the @entity2 Center Hospital due to @entity4 with @entity3 . The control group consisted of 33 @entity0 who had no resection without EPIC during the same periods. After combined cytoreductive surgery and EPIC, all @entity0 received systemic chemotheraphy with the exception of 2 @entity0 who could not tolerate the treatment. We retrospectively investigated the clinicopathologic features and analyzed the factors affecting the prognosis. Median follow-up period was 11.9 months (range 0.5~61 months). Statistical analysis was performed by SPSS 11.0 for Windows. A P-value less than 0.05 was considered as statistically significant. RESULTS: There was one case of the treatment-related mortality (5.5%) and seven cases of treatment-related complications (38%) in the combined cytoreductive surgery and intraperitoneal chemotherapy group. One-, 3- and 5-year survival rates of cytoreductive surgery plus EPIC were 57.6%, 25.9% and 13.0%, respectively, and those of the control group were 18.2%, 3% and 0%, respectively. Survival of the combined cytoreductive surgery plus EPIC group was better than that of the control group (p=0.0026). In multivariate analysis of prognostic factors affecting the survival, combined cytoreductive surgery plus EPIC (p=0.02) and systemic chemotherapy (p=0.019) were independent prognostic factors. CONCLUSION: Although a small number of cases were included in this study, combined cytoreductive surgery plus EPIC showed survival benefit and retained a comparable complication rate compared with the control group.

title: Combined Cytoreductive Surgery and Early Postoperative Intraperitoneal Chemotherapy for XXXX of @entity4 .

answer: @entity3


abstract: PURPOSE: Peritoneal seeding is the most common type of @entity1 or recurrence and one of the poor prognostic factors in @entity4 . Moreover, there are as yet no effective treatment modalities available. Recently some research groups suggested the benefit of combined cytoreductive surgery and intraperitoneal chemotherapy, but the related experiments remain in the trial stage. Therefore, we assessed the safety and evaluated the efficacy of combined cytoreductive surgery and early postoperative intraperitoneal chemotherapy (EPIC) in @entity4 @entity0 with @entity3 of @entity4 . MATERIALS AND METHODS: From Nov. 1997 to May. 2002, eighteen cases of combined cytoreduction and EPIC were performed in the @entity2 Center Hospital due to @entity4 with @entity3 . The control group consisted of 33 @entity0 who had no resection without EPIC during the same periods. After combined cytoreductive surgery and EPIC, all @entity0 received systemic chemotheraphy with the exception of 2 @entity0 who could not tolerate the treatment. We retrospectively investigated the clinicopathologic features and analyzed the factors affecting the prognosis. Median follow-up period was 11.9 months (range 0.5~61 months). Statistical analysis was performed by SPSS 11.0 for Windows. A P-value less than 0.05 was considered as statistically significant. RESULTS: There was one case of the treatment-related mortality (5.5%) and seven cases of treatment-related complications (38%) in the combined cytoreductive surgery and intraperitoneal chemotherapy group. One-, 3- and 5-year survival rates of cytoreductive surgery plus EPIC were 57.6%, 25.9% and 13.0%, respectively, and those of the control group were 18.2%, 3% and 0%, respectively. Survival of the combined cytoreductive surgery plus EPIC group was better than that of the control group (p=0.0026). In multivariate analysis of prognostic factors affecting the survival, combined cytoreductive surgery plus EPIC (p=0.02) and systemic chemotherapy (p=0.019) were independent prognostic factors. CONCLUSION: Although a small number of cases were included in this study, combined cytoreductive surgery plus EPIC showed survival benefit and retained a comparable complication rate compared with the control group.

title: Combined Cytoreductive Surgery and Early Postoperative Intraperitoneal Chemotherapy for @entity3 of XXXX .

answer: @entity4


abstract: AIM: The prevalence of interincisive and primate spaces in the primary dentition, relating them to age and sex, was studied. An analysis was made as to what extent various occlusal aspects of the arches affect the existence of spacing. MATERIALS AND METHODS: A population of 267 @entity0 , 153 males and 114 females, aged 2.2-8.2 years, was evaluated. All were white Caucasian, apparently healthy and lacking any @entity2 ; they had complete primary dentition and no erupted permanent teeth, without existing dental @entity2 and not having undergone any type of orthodontic treatment. Cast models were fabricated from impressions taken of all the @entity0 . Tooth sizes and interdental spaces were measured on these models and the various occlusal aspects were noted. RESULTS: The prevalence of spacing was high in the primary dentition, being independent of the chronological age of each @entity0 . Spacing was more frequent in males than in females. The presence or absence of spacing was not directly related to @entity1 except in cases of posterior cross-bite, where it was less frequently, and open-bites, in which spaces appeared more often than usual. CONCLUSION: Spaces in the primary dentition were very common among the population studied and more frequent in male @entity0 than in females. Primate spaces were more frequent at the earliest ages, but chronological age had no influence on the presence of interincisive spacing. The lack of the spaces in the maxillary arches, typical of the primary dentition, prevailed among individuals with posterior cross-bite, contrary to what normally happens in the rest of the population.

title: Diastemas in primary dentition and their relationships to sex, age and dental XXXX .

answer: @entity1


abstract: BACKGROUND: Real-time sonoelastography is currently used for the characterization of superficial solid lesions such as thyroid and breast masses. This study evaluates the usefulness of percutaneous sonoelastography for the characterization of solid focal @entity3 . METHODS: 30 out of 43 @entity0 with 38 known @entity3 were included in a prospective, diagnostic study. Qualitative analysis (pattern of deformation, @entity2 ) and semi-quantitative measurements (strain ratio, @entity4 percentage, histogram) were evaluated. Sensitivity, specificity, positive and negative predictive values were calculated and the area under the receiver operating characteristics curve was constructed. RESULTS: Patterns A and C-D are specific of benign lesions and @entity1 respectively. The patterns for haemangiomas, @entity5 and @entity1 were significantly different to each other in terms of strain ratio, @entity4 percentage and histogram (p<0.05). A statistically significant difference (p<0.001) was observed between the median values of the 3 measured parameters for benign (1.02; 12%; 47) and malignant lesions (1.66; 65%; 20.5) respectively. The area under the receiver operating characteristics curve values for strain ratio, @entity4 percentage and histogram were 0.88, 0.89, and 0.86 respectively for cut-off values of 1.2, 45, and 30. CONCLUSIONS: By percutaneous sonoelastography it is possible to differentiate benign versus malignant focal @entity3 , @entity1 in particular, with good diagnostic performance.

title: Percutaneous real-time sonoelastography as a non-invasive tool for the characterization of solid focal XXXX : A prospective study.

answer: @entity3


abstract: Since 1974, a concerted effort has been made to identify and biopsy all @entity6 in @entity0 presenting with @entity2 . From 1974 until July 1982, 247 @entity0 had initial cervical exploration for @entity2 . The percentage of @entity0 in whom four or more glands were identified rose from 53 per cent in 1974 to as high as 88 per cent, with a mean of 80 per cent during the 8.5-year period. Ectopic location, prior thyroid surgery, and detrimental effects of prolonging surgery in some @entity0 are reasons precluding localization of all glands in every @entity0 . The percentage of biopsies positive for parathyroid tissue rose from 78 per cent in 1974 to 94 per cent in 1982. Routine biopsy of all glands provided the following results of classification in the 247 cases: @entity3 , 56 per cent; @entity4 , 18 per cent; @entity9 , 24 per cent; @entity1 , 0.8 per cent; and in three cases, four normal glands were identified. The one major complication was a case of temporary bilateral recurrent @entity7 . Mean follow-up period is 3 years. There was no case of permanent @entity8 and no operative deaths. Persistence and recurrence rates are 4.9 per cent and 0.4 per cent, respectively. Four of the @entity0 with persistence and the one @entity0 with recurrence have required reexploration. All but one of these was considered cured by reoperation. Eight of the 12 @entity0 with initial persistent @entity5 postoperatively have been managed conservatively. These results suggest routine attempts to identify and biopsy all glands can be performed with minimal risk and complications and without permanent @entity8 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: The role of routine biopsy of all @entity6 in XXXX .

answer: @entity2


abstract: Since 1974, a concerted effort has been made to identify and biopsy all @entity6 in @entity0 presenting with @entity2 . From 1974 until July 1982, 247 @entity0 had initial cervical exploration for @entity2 . The percentage of @entity0 in whom four or more glands were identified rose from 53 per cent in 1974 to as high as 88 per cent, with a mean of 80 per cent during the 8.5-year period. Ectopic location, prior thyroid surgery, and detrimental effects of prolonging surgery in some @entity0 are reasons precluding localization of all glands in every @entity0 . The percentage of biopsies positive for parathyroid tissue rose from 78 per cent in 1974 to 94 per cent in 1982. Routine biopsy of all glands provided the following results of classification in the 247 cases: @entity3 , 56 per cent; @entity4 , 18 per cent; @entity9 , 24 per cent; @entity1 , 0.8 per cent; and in three cases, four normal glands were identified. The one major complication was a case of temporary bilateral recurrent @entity7 . Mean follow-up period is 3 years. There was no case of permanent @entity8 and no operative deaths. Persistence and recurrence rates are 4.9 per cent and 0.4 per cent, respectively. Four of the @entity0 with persistence and the one @entity0 with recurrence have required reexploration. All but one of these was considered cured by reoperation. Eight of the 12 @entity0 with initial persistent @entity5 postoperatively have been managed conservatively. These results suggest routine attempts to identify and biopsy all glands can be performed with minimal risk and complications and without permanent @entity8 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: The role of routine biopsy of all XXXX in @entity2 .

answer: @entity6


abstract: Counselling was made a statutory requirement for clinics providing assisted reproduction services as a result of the concern raised that these treatments would raise uniquely challenging emotional and ethical problems for @entity0 . Before the @entity0 Fertilisation and Embryology Act 1990, few counsellors specialized in this field and there were no standards for their training or experience. In the intervening years considerable progress has been made in these areas. The research evidence, which informs their practice concerning the impact of @entity1 and its treatment, has also grown very substantially. There is now a reasonable consensus about the broad nature of the emotional and psychological sequelae, although many unexplored questions remain. In addition, the literature providing evidence for the efficacy and effectiveness of counselling in other areas has developed in both quantity and sophistication. Counsellors are often well-placed to work with @entity0 groups and also with the multidisciplinary assisted conception team itself on the very difficult psychosocial and ethical issues faced in practice. The sophisticated research in these fields has not yet been done in the context of @entity1 ; it is therefore necessary to extrapolate from other fields, especially in mental health practice. This article will argue that there is now ample evidence to support the decisions made by legislators in requiring counselling to be available to @entity0 in assisted conception units. The @entity1 counselling profession is in a position to begin contributing to the generation of research relevant to this field.

title: Counselling--its role in the XXXX team.

answer: @entity1